The studies span multiple tumor types—including pancreatic, biliary, renal, gastric, lung, ovarian, and esophageal cancers—and collectively demonstrate the power of Geneseeq’s multi-omics platform, integrating whole-genome sequencing, fragmentomics, and AI-driven modeling for non-invasive cancer detection. In addition, SCENT-2 trial study, which was selected for oral presentation (Abstract #7006), evaluated the combination of sintilimab and chidamide followed by P-GemOx in treatment-naïve ENKTL patients using Geneseeq Hemasalus panel.

All studies were conducted in collaboration with leading cancer centers and reflect Geneseeq’s mission to transform oncology through integrated genomics and AI-powered innovation.

Featured Presentations at ASCO 2025:

About Geneseeq:

Geneseeq Technology Inc. (Geneseeq) is a research-driven leader in precision oncology, utilizing cutting-edge next-generation sequencing (NGS) technologies to advance cancer care. The company provides comprehensive genomic profiling solutions for all tumor types, including pan-cancer and cancer-specific panels, alongside cutting-edge tools for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Geneseeq has reached key regulatory milestones to date, including CE-IVD certification for its solid tumor and hematologic cancer panels, and FDA Breakthrough Device Designation for its MCED test, CanScan®. The company has also received approval from the National Medical Products Administration (NMPA) for GeneseeqPrime, designed for tumor mutational burden (TMB) detection in lung cancer.

The post Geneseeq Showcases Cutting-Edge Liquid Biopsy Research Across Multiple Cancer Types at ASCO 2025 appeared first on Geneseeq Technology Inc. | A Precision Oncology Company.

At AACR 2025, Geneseeq will showcase seventeen posters from both internal research and collaborative efforts, spanning minimal residual disease (MRD), cancer genomics, biomarker identification, and treatment response—reinforcing our commitment to innovation and excellence across multiple domains, from discovery to clinical impact.

The post Geneseeq Technology Inc. to showcase seventeen studies at 2025 American Association for Cancer Research (AACR) annual meeting appeared first on Geneseeq Technology Inc. | A Precision Oncology Company.

The following is a summary of our studies that will be presented at ASCO 2024：

Poster 1 (Bd# 276) A multi-center study for colorectal cancer early detection among patients with high-risk disease using a cell-free fragmentomics assay.

Poster 2 (Bd# 34) Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma.

Poster 3 (Bd# 153) Fragmentomics of cell-free DNA as a sensitive biomarker for early detection of pancreatic cancer.

Poster 4 (Bd# 83) Molecular characterization and biomarker identification in pediatric B-cell acute lymphoblastic leukemia.

Poster 5 (Bd# 460) Genomic profiling of non-small cell lung cancer with rare aberrations in EGFR codon L858 and the survival outcome under real-world first-line EGFR tyrosine kinase inhibitor treatment compared to classic EGFR^L858R

The post Geneseeq AT ASCO 2024 appeared first on Geneseeq Technology Inc. | A Precision Oncology Company.

Geneseeq’s mini-oral presentations will release the most recent results from multi-cancer early detection(MCED) case-control study and the “Jinling cohort,” a 15,000-participant perspective MCED cohort study. In addition to the mini-oral presentations, Geneseeq will present ten posters featuring a diverse range of studies covering various aspects of minimal residual disease (MRD), cancer genomics and biomarker identification.

The post Geneseeq to Showcase Twelve Studies at 2024 American Association for Cancer Research (AACR) Annual Meeting appeared first on Geneseeq Technology Inc. | A Precision Oncology Company.

The post GENESEEQ TO SHARE EIGHT COLLABORATED STUDIES AT WCLC 2023 appeared first on Geneseeq Technology Inc. | A Precision Oncology Company.

In this study, the research team from Sun Yat-sen University Cancer Center and Geneseeq Technology Inc. further performed genomic profiling of the pre-treatment tumor tissues of these patients by whole-exome sequencing (WES) aiming to identify biomarkers related to treatment outcomes. Although tumor mutation burden (TMB) is a promising biomarker for immune-oncology (IO) therapies in certain cancer types, it was not for NPC. As a result, NPC-specific molecular biomarkers that can potentially predict treatment response are urgently needed.

Furthermore, the researchers identified the granzyme pathway that has recently been proven to associate with IO therapy outcome in other cancer types, especially GZMB and GZMH. Results showed that patients, who experienced gene copy number loss of GZMB or GZMH, had a significantly lower response rate to the treatment and a lower survival rate compared to the patients without such gene loss. Moreover, the researchers also characterized other key immune-related pathways including gasdermin family and IFN, among which copy number loss in GZMB and GZMH occurred at the highest frequency.

“Knowing the copy number alterations in granzymes sheds light on the long-term survival and the disease’s biomarkers responding to anti-PD-1 treatment in NPC patients.” Says Dr. Hua Bao, author and the Director of Research & Development at Geneseeq. “Moving forward, we would like to prospectively examine such biomarkers for predicting IO therapy outcomes in NPC patients and provide more insights into granzymes’ function during immunotherapy.”

The post Genomic Study Uncovers New Biomarkers for the Efficacy of Immunotherapy in Nasopharyngeal Carcinoma (NPC) Patients  appeared first on Geneseeq Technology Inc. | A Precision Oncology Company.

The post New biomarkers to predict patients’ clinical outcomes to ICI therapy in lung cancer appeared first on Geneseeq Technology Inc. | A Precision Oncology Company.